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T Vervliet, JB Parys and G Bultynck
Antiapoptotic Bcl-2-family members are well known for their ‘mitochondrial’ functions as critical neutralizers of proapoptotic Bcl-2-
family members, including the executioner multidomain proteins Bax and Bak and the BH3-only proteins. It has been clear for more
than 20 years that Bcl-2 proteins can impact intracellular Ca2+ homeostasis and dynamics. Moreover, altered Ca2+ signaling is
increasingly linked to oncogenic behavior. Speciﬁcally targeting the Ca2+-signaling machinery may thus prove to be a valuable
strategy for cancer treatment. Over 10 years ago a major controversy was recognized concerning whether or not Bcl-2 proteins
exerted their antiapoptotic functions via Ca2+ signaling through lowering the ﬁlling state of the endoplasmic reticulum (ER) Ca2+
stores or by suppressing Ca2+ release from the ER without affecting the ﬁlling state of this Ca2+ store. Further research from
different laboratories indicated a wide variety of mechanisms by which Bcl-2-family members can impact Ca2+ signaling. In this
review, we propose that antiapoptotic Bcl-2-family members are multimodal regulators of intracellular Ca2+-signaling events in cell
survival and cell death. We will discuss how different Bcl-2-family members impact cell survival and cell death by regulating Ca2+
transport systems at the ER, mitochondria and plasma membrane and by impacting the organization of organelles and how these
insights can be exploited for causing cell death in cancer cells. Finally, we propose that the existing controversy reﬂects the diversity
of links between Bcl-2 proteins and Ca2+ signaling, as certainly not all targets or mechanisms will be operative in every cell type and
every condition.
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INTRODUCTION
Ca2+ signaling is one of the most versatile and extensively used
forms of intracellular communication.1 The major intracellular
Ca2+-storage organelle is the endoplasmic reticulum (ER), but also
the Golgi apparatus and the lysosomes can store Ca2+. Ca2+
storage in the ER is achieved by the action of the sarco/
endoplasmic reticulum ATPase (SERCA)2 and of the intraluminal ER
Ca2+-binding proteins, BiP, calreticulin and calnexin.3 In virtually all
cells, the release of Ca2+ from the ER is mediated by inositol
1,4,5-trisphosphate (IP3) receptors (IP3Rs), which are tetrameric
IP3-gated Ca
2+-permeable channels of which three isoforms exist.4
Many tissues express several IP3R isoforms, although IP3R1
appears enriched in neurons, IP3R2 in heart and in liver and
IP3R3 in lymphocytes and in many cell lines.
5 Their Ca2+-ﬂux
properties are tightly controlled by cellular factors like Ca2+, ATP,
kinases and phosphatases and regulatory proteins, including
tumor suppressors and proto-oncogenes.5 In skeletal and cardiac
muscle cells, Ca2+ intended for contraction is released by
ryanodine receptors (RyRs).6 RyRs form another class of ER-
located tetrameric Ca2+-release channels that are related to the
IP3Rs and of which also three isoforms exist.
7 The resulting Ca2+
signals display speciﬁc spatiotemporal characteristics,8 thereby
controlling specialized processes at different subcellular locations,
like the fusion of secretory vesicles with the plasma membrane
and transcriptional regulation in the nucleus. Depending on the
intracellular conditions these Ca2+ signals can occur as a
prolonged elevation of the Ca2+ concentration, a single Ca2+
transient or as long-lasting Ca2+ oscillations. Finally, the Ca2+
released from the ER can be extruded out of the cell via plasma
membrane Ca2+-ATPases (PMCAs)9 and Na+/Ca2+ exchangers.10 As
a consequence, adequate long-term ER Ca2+ homeostasis requires
Ca2+ inﬂux from the extracellular environment. This is mediated by
store-operated Ca2+ entry10 mechanisms, whose molecular
components consist of the ER Ca2+ sensors Stim1 and Stim2 and
the tetrameric plasmalemmal Ca2+-inﬂux channels Orai1, Orai2
and Orai3.11 Besides this, Ca2+ inﬂux across the plasmamembrane
can also be mediated by other channels like purinergic channels
(P2X receptors),12 voltage-gated Ca2+ channels13 and transient
receptor potential channels.14
In order to control the Ca2+ concentration at various subcellular
locations, close contact sites exist between the ER Ca2+-storage
organelle and other organelles15 like the mitochondria,16 thereby
exerting a mutual impact on each other’s functions. The ER–
mitochondrial connection is critical for the control of cell death
and survival processes in cells.17,18 These contact sites can be
isolated as mitochondria-associated ER membranes and a growing
number of proteins have been identiﬁed in the mitochondria-
associated ER membranes, including mitofusins, chaperones like
glucose-regulated protein 75, Sigma-1 receptors, protein kinase
RNA-like endoplasmic reticulum kinase.19–22 Also Ca2+-transport
systems such as IP3Rs and voltage-dependent anion channels
(VDACs) are present in the mitochondria-associated ER
membranes.21 As a consequence, there is a ‘quasi-synaptic’
Ca2+-signaling pathway from the ER to the mitochondria,23 where
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a strong driving force for Ca2+ accumulation exists due to the
large negative membrane potential (Δψ of about − 180 mV) across
the inner mitochondrial membranes.24 These close contact sites
overcome the inherent low-afﬁnity Ca2+-transport properties of
the inner mitochondria-located mitochondrial Ca2+ uniporter25,26
by creating microdomains where local Ca2+ concentrations can
rise up to 20 μM upon opening of IP3Rs, allowing efﬁcient
mitochondrial Ca2+ uptake during physiological signaling.27
Mitochondrial Ca2+ is efﬁciently extruded from the mitochondrial
matrix via Na+/Ca2+ and H+/Ca2+ exchangers.28
CA2+ SIGNALING IN CANCER
Ca2+ signals control cancer hallmarks
Besides controlling a plethora of cell physiological processes,
intracellular Ca2+ signals can impact and control several hallmarks
of oncogenesis and cancer progression, including enhanced cell
survival and bioenergetics, increased cell-death resistance, cell
proliferation and migration.
First, the ER Ca2+-signaling events impact mitochondrial
functions like cell survival via a stimulation of ATP production
and cell death via the release of cytochrome c and other
proapoptotic factors.29,30 Ca2+ oscillations can drive mitochondrial
bioenergetics by stimulating the production of NADH and ATP.
Three enzymes that are sensitive to Ca2+ and that operate or feed
substrates within the tricarboxylic acid cycle are pyruvate
dehydrogenase, isocitrate dehydrogenase and α-ketoglutarate
dehydrogenase.24 IP3R activity is critical for the occurrence of
these Ca2+ oscillations. Inhibiting IP3R activity or suppressing IP3R
expression results in dampened mitochondrial bioenergetics,
triggering the activation of AMP-dependent kinase and the
subsequent induction of autophagy, a catabolic process that can
overcome periods of nutrient starvation.31,32
Second, intracellular Ca2+ signals can also provoke cell death.
Classically, activation of Bax and Bak, two proteins of the Bcl-2
family (see further), leads to mitochondrial outer membrane
permeabilization (MOMP) and the release of cytochrome c and
other proapoptotic factors from the cristae into the cytosol,
switching on the apoptotic cascade. Aberrant Ca2+ signals can also
lead to a similar phenomenon leading to Ca2+-induced MOMP.33
In contrast to Ca2+ oscillations, excessive Ca2+-release events
translate into mitochondrial Ca2+ overload and mitochondrial
reactive oxygen species (ROS) production, triggering the opening
of the mitochondrial permeability transition pore. This results in
mitochondrial swelling and rupture of the mitochondrial
membranes,34 leading to the release of cytochrome c and other
proapoptotic factors. The transfer of those proapoptotic Ca2+
signals from the ER into the mitochondria appears to be
preferentially mediated by the type 3 IP3R and type 1 VDAC
channel.35 Recently, the molecular mechanisms linking Ca2+ to
mitochondrial permeability transition pore opening have been
identiﬁed. Mitochondrial Ca2+ overload results in cardiolipin
oxidation and disassembly of the respiratory chain complex 2,
leading to uncontrolled ROS production.36 Cytosolic Ca2+ can also
mediate MOMP by activating calcineurin, causing the depho-
sphorylation of the proapoptotic BH3-only protein Bad and its
subsequent release from 14-3-3 proteins.37 Dephosphorylated Bad
targets and inhibits antiapoptotic Bcl-XL proteins, resulting in the
de-inhibition of Bax and Bak.
Third, intracellular Ca2+ also controls cell proliferation and cell
cycle progression.38 For instance, prosurvival Ca2+ oscillations can
activate calcineurin, which dephosphorylates the transcription
factor nuclear factor of activated T cells, thereby enhancing cell
proliferation. Nuclear factor of activated T-cell activation and
proliferation occurs downstream of plasmalemmal Ca2+-inﬂux
channels, like Orai1 and TRPV6.39,40 Ca2+ also regulates during the
passage from G1 to S-phase the expression of immediate-early
genes, such as JUN, FOS and MYC but also the activation
and inactivation of RAS, all of which are proto-oncogenes.
Furthermore, increased mitochondrial bioenergetics in response
to mitochondrial Ca2+ uptake can lead to increased cell
proliferation.38
Fourth, Ca2+ signals also regulate aspects of migration and
metastasis.41 Ca2+ release during metastasis has been linked to the
activation of calpains and myosin light-chain kinase, involved in
dissociation from the extracellular matrix and subsequent retrac-
tion of the rear end of the cell required for cell migration.
The store-operated Ca2+ entry components, Stim1 and Orai1, have
been implicated in breast cancer metastasis.42 Knock down of
Stim1 or Orai1 or functional inhibition of store-operated Ca2+
entry using inhibitors suppressed breast cancer metastasis to
tissues like the lungs. Follow-up work conﬁrmed that Orai1 knock
down in breast cancer cells interfered with the invasiveness of
these cells.43
Taken together this demonstrates that the regulation of the
complex spatiotemporal Ca2+ signals can sustain cancer cells in
their tumor activity. Not unexpectedly, many chemotherapeutic
reagents can trigger ‘toxic’ Ca2+ signals, essential for their
therapeutic effectiveness.44
Cancer cells display altered Ca2+ signaling
Also, the importance of Ca2+ signaling in cancer development is
becoming increasingly clear.38,41,45–48 At the molecular level, Ca2+
signaling is altered in cancer cells via at least two major
mechanisms.
First, an increasing number of survival proteins, proto-
oncogenes and tumor suppressors appear to execute an
important part of their function at the ER, the ER–mitochondrial
interface or the mitochondrial membranes, thereby directly or
indirectly controlling Ca2+ release from the ER and Ca2+ uptake
into the mitochondria.49,50 For instance, the tumor suppressor p53
activates SERCA upon cell stress, resulting in mitochondrial Ca2+
overload.51 This mechanism is critical for the cellular response to
chemotherapy, which promotes extra-nuclear p53 to bind to and
activate SERCA, promoting ER Ca2+ overload and subsequently
mitochondrial Ca2+ overload. Other examples include the tumor
suppressor BRCA1 that directly binds to IP3Rs, enhancing its
Ca2+-release properties52 and the prosurvival protein kinase B that
phosphorylates the IP3R, thereby dampening its proapoptotic
Ca2+-release properties, while the protein phosphatase 2A
counteracts this process. Interestingly, protein phosphatase 2A
recruitment to the IP3R3 complex is enhanced by the tumor
suppressor promyelocytic leukemia protein.53
Second, cancer cells typically display altered expression proﬁles,
localization or functional properties of Ca2+-transport systems or
of their regulatory proteins, thereby favoring oncogenesis. For
instance, prostate cancer cells appear to switch their Orai-isoform-
expression proﬁle from Orai1 to Orai3, thereby increasing cell
death resistance and promoting cell proliferation by disfavoring
the formation of store-operated Ca2+ entry channels while
favoring the formation of arachidonate-regulated ca2+ channels
channels.54 In women diagnosed with breast cancer a high
Stim1/Stim2 ratio is associated with a poorer prognosis.43 RyR3
upregulation has been implicated in breast cancer cell lines and
patient samples, where its expression was linked to a poor
disease-free survival rate.55 Also, several transient receptor
potential channels have been implicated in cancer progression,
especially in prostate and breast cancers.56 A recent study also
showed that Ca2+ signaling may be in involved epigenetic
remodeling of certain tumor suppressor genes.57
An important protein family involved in the regulation of cell
survival, cell death and cancer development is the Bcl-2-protein
family.58,59 Clearly, this protein family impacts many aspects of
Ca2+ signaling, but the ﬁeld was fraught with multiple
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controversies, as highlighted by Distelhorst and Shore more than
10 years ago.60 However, further research has revealed a plethora
of targets and functions of Bcl-2-family members related to
intracellular Ca2+ signaling and its role in cell survival and cell
death in normal and malignant cells. As such, the ‘apparent’
controversial ﬁndings may simply reﬂect the complex network of
molecular and functional links between Bcl-2 proteins and Ca2+
signaling. In this review, we therefore aimed to summarize and
integrate the recent developments and emerging insights in the
different mechanisms by which Bcl-2-family members exploit the
Ca2+-signaling machinery to impact oncogenic features like cell
survival and cell death resistance (Figure 1).
THE BCL-2-PROTEIN FAMILY
Proteins of the Bcl-2-protein family are very well known for their
functions as critical regulators of MOMP.61,62 Three types of
Bcl-2-family members are expressed in cells: (i) antiapoptotic
Bcl-2-family members (i.e. Bcl-2, Bcl-XL, Mcl-1, Bcl-10, Bﬂ-1), which
are characterized by four Bcl-2 homology (BH) domains, appearing
from the N- to the C-terminus in the order BH4, BH3, BH1 and BH2.
(ii) Proapoptotic multidomain Bcl-2-family members (i.e. Bax, Bak
and Bok), characterized by at least three BH domains and
(iii) proapoptotic BH3-only proteins, which contain only one BH3
domain.63 However, further structural work led to a proposed
consensus motif for a BH4 domain (i.e. ϕ1 ϕ2 X X ϕ3 ϕ4, where X
is any amino acid, ϕ is hydrophobic amino acid and ϕ3 is an
aromatic amino acid) that was identiﬁed not only in Bcl-2 and
Bcl-XL, but also in several other Bcl-2-family members, including
Mcl-1, A1, Bax, Bak, Bid and Bim.64,65 MOMP is classically executed
by the activation and oligomerization of Bax and Bak proteins,
forming pores that mediate the release of cytochrome c and other
proapoptotic factors.63,66 BH3-only proteins are typically divided in
direct activators of Bax/Bak (like Bid and Bim) and in sensitizers
that can antagonize antiapoptotic Bcl-2 proteins but fail to directly
activate Bax/Bak (like Bad, Noxa, Puma).61 In particular, antiapop-
totic Bcl-2-family members, through their hydrophobic cleft, which
is formed by the BH3, BH1 and BH2 domains, scaffold and
neutralize the proapoptotic Bcl-2-family members. Several studies
highlighted the importance of the hydrophobic cleft of Bcl-2
Figure 1. An integrative overview on the regulation of intracellular Ca2+ signaling by Bcl-2-family proteins in cell death and survival. This ﬁgure
depicts the complex molecular network of interactions and functional interplay between Bcl-2-family members and intracellular Ca2+
signaling in the control of cell death and survival processes. On the one hand, excessive Ca2+-release events (left graph) cause cell death via at
least two independent mechanisms that converge at the mitochondria. Strong Ca2+-release events from the ER can lead to mitochondrial Ca2+
overload. This results in opening of the mitochondrial permeability transition pore (mPTP), mitochondrial swelling, rupture and the eventual
release of cytochrome c (and other proapoptotic factors) and the induction of apoptosis. In addition to this, these Ca2+ signals can also
activate the phosophatase calcineurin, which dephosphorylates Bad, causing its release from 14-3-3 proteins. Dephosphorylated Bad can bind
to Bcl-XL, antagonizing its antiapoptotic properties, resulting in Bax/Bak activation, MOMP and thus apoptosis. On the other hand, Ca
2+
oscillations have been implicated in promoting bioenergetics, cell survival, proliferation and metastasis. This is caused by an increased activity
of Ca2+-dependent TCA enzymes responsible for ATP production and by an increased nuclear factor of activated T cell (NFAT) signaling via
calcineurin activation. Bcl-2-family members impact different aspects of the Ca2+-signaling machinery. First, antiapoptotic Bcl-2-family
members prevent proapoptotic Ca2+ signaling via different mechanisms. Bcl-2 directly inhibits proapoptotic Ca2+ release from the IP3R at the
ER via its BH4 domain. In addition to this, at the IP3R Bcl-2 serves as a docking platform for DARPP-32 and calcineurin. Both Bcl-2 and Bcl-XL
also prevent mitochondrial Ca2+ overload by inhibiting VDAC1-mediated mitochondrial Ca2+ uptake. Bcl-2 has been implicated in promoting
basal ER Ca2+ leak, which indirectly suppresses proapoptotic Ca2+-release events from the ER and thus prevents mitochondrial Ca2+ overload.
At least, two mechanisms are responsible for this: (i) Bcl-2 can promote the ER Ca2+-leak properties of Bax inhibitor-1 and (ii) Bcl-2 can sensitize
IP3R1 channels via a mechanism that involves PKA-mediated phosphorylation of the IP3R1. JNK-mediated phosphorylation of Bcl-2 alleviates
Bcl-2’s effects on the ER Ca2+ leak. The exact mechanism for this is still unknown but may involve a loss in binding to proapoptotic Bcl-2 family
members. Second, different antiapoptotic Bcl-2-family members, including Bcl-2, Bcl-XL and Mcl-1, promote prosurvival Ca
2+ oscillations by
stimulating IP3R-mediated Ca
2+ oscillations. Bcl-XL and Mcl-1 have been suggested to promote Ca
2+ uptake via VDAC1 (and VDAC3),
increasing the transfer of prosurvival Ca2+ signals to the mitochondria and ensuring proper mitochondrial activity. The Mcl-1/VDAC1 complex
was speciﬁcally implicated in metastasis. In addition, by modulating the mitochondrial Na+/Ca2+ transporter, Bcl-2 may also regulate Ca2+
levels in the mitochondrial matrix. Finally, it is important to note that Bcl-2-family members critically control the organization and/or dynamics
of the ER and mitochondria. Abolishing the binding of Bcl-2 to Bax or Bak at the ER may also trigger ER reorganizations that can lead to a loss
of ER integrity and dysregulated ER Ca2+ homeostasis. Blue arrows indicate the uptake or release of Ca2+. Abbreviation: MCU, mitochondrial
Ca2+ uniporter.
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proteins for their antiapoptotic properties.67 These insights have
been exploited to develop the so-called BH3-mimetic drugs that
can bind to the hydrophobic cleft and therefore inhibit
antiapoptotic Bcl-2 proteins.67–69 The upregulation of antiapoptotic
Bcl-2 proteins is essential for the survival of certain cancer cells.70
As such, increased BH3-only protein levels, like Bim, render cancer
cells addicted to high levels of antiapoptotic Bcl-2 proteins at the
level of the mitochondria. These cancer cells are prone to Bcl-2
antagonism using BH3 mimetics and/or destabilization by
ubiquitin-dependent degradation mechanisms.71,72 Besides the
hydrophobic cleft, also the BH4 domain of antiapoptotic Bcl-2-
family members is essential for their antiapoptotic function, since
Bcl-2ΔBH4 fails to scaffold Bax to prevent apoptosis and is even
proapoptotic.73,74 This is underpinned by a recent study using
stapled BH4-domain peptides as novel, high-afﬁnity inhibitors of
Bax activation and Bax-mediated apoptosis.75 Also, a recently
identiﬁed Bcl-2 antagonist that targets the BH4 domain (BDA-366)
impacts Bcl-2 structure and causes exposure of its BH3 domain,
switching Bcl-2 in a Bax-activating protein.76
There is accumulating evidence that Bcl-2’s antiapoptotic
properties do not solely depend on interactions with proapoptotic
Bcl-2-family members at the mitochondrial level. Also actions at
the level of the ER and the plasma membrane contribute to Bcl-2’s
antiapoptotic effects.77–79 This correlates with the ﬁndings that
different Bcl-2-family proteins, including Bcl-2, Bax/Bak and Bok,
are also localized at sites outside the mitochondria.80–82 In
particular, the ER has received major attention as an important
site of action for Bcl-2 functions in apoptotic cell death. More than
20 years ago, the ﬁrst reports about antiapoptotic Bcl-2 proteins
modulating intracellular Ca2+ homeostasis and dynamics
at the level of the ER emerged.83–85 It became clear that
antiapoptotic Bcl-2 suppressed Ca2+ release from the ER.84 Since
a ‘quasi-synaptic signaling’ exists between ER and mitochondria,
dampening ER Ca2+ release prevents mitochondrial Ca2+ overload
and thus Ca2+-triggered MOMP.18,19,86 However, the underlying
mechanistic basis for these actions of Bcl-2 at the ER has caused a
long-standing divide in the ﬁeld, as reviewed by Distelhorst and
Shore 10 years ago in this journal,60 thereby representing two
main views: (i) Bcl-2 lowers steady-state luminal ER Ca2+ levels
(originally described in Pinton et al.87) or (ii) Bcl-2 suppresses
Ca2+-release events from the ER without affecting the ER
Ca2+-store content (originally described in He et al.88 and
Thomenius and Distellhorst89).
Now, 10 years later, we can state that the controversy
concerning Bcl-2-family proteins their role in controlling Ca2+
signaling may reﬂect the emerging diversity of the Ca2+-transport
systems that are directly or indirectly modulated by Bcl-2-family
proteins and of the different ways in which they can impact the
properties of these Ca2+-transport systems. These Ca2+-transport
systems include Ca2+-permeable channels like the IP3Rs,
90 RyRs,91
Bax inhibitor-1(ref. 90) and the mitochondria-located VDACs93–95
and Ca2+ pumps like SERCA96 and PMCA97 (Table 1). For a detailed
discussion on the role of these Ca2+ transporters in controlling cell
survival, cell death or cancer, we would like to refer to other
reviews handling this topic.17,18,98–101 Furthermore, the impact of
Bcl-2 proteins on Ca2+ signaling may not be limited to controlling
cell death and survival, but can also be involved in non-apoptotic
functions, increasing the complexity.102,103
BCL-2-PROTEIN FAMILY TARGETS AT THE ER
Ca2+ oscillations are known to promote mitochondrial bioener-
getics, activating nuclear factor of activated T cells and promoting
cell proliferation and survival.104 In contrast, a high amplitude or
sustained Ca2+ release is associated with an excessive Ca2+
transfer to the mitochondria leading to MOMP and the induction
of cell death.18 Cancer cells have developed several mechanisms
that favor the occurrence of prosurvival Ca2+ signals while
inhibiting excessive Ca2+ transfer to the mitochondria. At the ER
Ca2+ release can be modulated to promote Ca2+ oscillations while
limiting proapoptotic Ca2+ release. Controlling the ﬁlling state of
the ER Ca2+ store is also an important means to prevent excessive
Ca2+ transfer into the mitochondria. Strikingly, the Bcl-2-protein
family has been involved in regulating all of the above
mechanisms.
Table 1. Interactions between Bcl-2-protein family members and the Ca2+ toolkit
Ca2+-transport system Interacting
Bcl-2-family
member
Effect on Ca2+-transport system Functions in cell death or cell survival Ref.
Bcl-2-family proteins targets at the ER
IP3R Bcl-2 Inhibition of IP3R-mediated Ca
2+ release Prevents proapoptotic Ca2+ transfer to
mitochondria
90,104,133–136
Promotes Ca2+ oscillations Stimulation of mitochondrial bioenergetics 138,148
Bcl-XL Promotes Ca
2+ oscillations Stimulation of mitochondrial bioenergetics 144,147,150
Mcl-1 Promotes Ca2+ oscillations Stimulation of mitochondrial bioenergetics 138
Bok Protects against caspase 3-mediated cleavage Unknown 214
Bax inhibitor-1 Bcl-2 Increased ER Ca2+ leak Protects against apoptosis 117,121
SERCA Bcl-2 Protects SERCA function, increased expression Maintain proper ER Ca2+ homeostasis 88,130
Destabilizes SERCA Reduced ER store content 128,129,131
RyR Bcl-2 Inhibition of RyR-mediated Ca2+ release Unknown 91
Bcl-XL Inhibition of RyR-mediated Ca
2+ release Unknown 162
Bcl-2-family proteins targets at the mitochondria
VDAC Bcl-2 Inhibition of mitochondrial Ca2+ uptake Prevents mitochondrial Ca2+ overload and
cell death
93,95
Bcl-XL Regulation of mitochondrial Ca
2+ uptake Prevents mitochondrial Ca2+ overload and
cell death
94,178,180
Stimulation mitochondrial bioenergetics 182
Mcl-1 Increased mitochondrial Ca2+ uptake and ROS
production
Increased cell migration/metastasis 187
Na+/Ca2+ exchanger Bcl-2 Reduced Ca2+ extrusion from mitochondrial matrix Increased NADH production 188
Bcl-2-family proteins targets at the plasma membrane
PMCA Bcl-2 Inhibition of Ca2+ extrusion from the cytosol Shift from apoptotic to necrotic cell death 97
Bcl-2 proteins and calcium signaling
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Bcl-2-family proteins regulate the ER Ca2+ pool
It was proposed that antiapoptotic Bcl-2 could lower the steady-
state ER Ca2+ levels.87 Since the level of ﬁlling of the ER Ca2+ stores
determines the potential amount of Ca2+ transferred into the
mitochondria, lowering the ER Ca2+ levels is an effective way to
limit proapoptotic ER–mitochondrial Ca2+ transfer.105 But it may
come at a cost given that a decreased ER Ca2+ content can trigger
ER stress and may result in activation of the proapoptotic arm of
the unfolded protein response (UPR).106–108 Nevertheless, a model
in which the ratio of antiapoptotic over proapoptotic Bcl-2-family
members dictates ER Ca2+ levels was supported by the fact that
Bax/Bak-deﬁcient cells displayed decreased ER Ca2+ levels.82 At the
mechanistic level, it was found that in Bax/Bak-deﬁcient cells IP3Rs
were ‘leaky’ due to their increased sensitivity to IP3. As such, basal
IP3 levels could be sufﬁcient to open the IP3R channel, mediating
an increased basal ER Ca2+ leak. The sensitization of the IP3R was
found to be caused by hyperphosphorylation of the IP3R1
channels by protein kinase A (PKA) at Ser1755.109 Bcl-2 knock
down led to a decreased PKA-dependent phosphorylation of the
IP3R1, thereby suppressing basal ER Ca
2+ leak and restoring
normal ER Ca2+ levels. Recently, further mechanistic insights
indicated that Bcl-2 may be part of a multiprotein complex
responsible for recruiting other regulatory proteins. Bcl-2 served as
a docking platform for both dopamine- and cAMP-regulated
phosphoprotein of 32 kDa (DARPP-32) and calcineurin, dynami-
cally controlling IP3R1 phosphorylation and activity. In response to
T-cell-receptor activation, IP3R1 becomes hyperphosphorylated
due to both PKA activation and the inhibition of the protein
phosphatase 1, caused by the PKA-dependent phosphorylation of
DARPP-32. Subsequent Ca2+ release through IP3Rs locally activates
calcineurin, which dephosphorylates DARPP-32, abolishing its
protein phosphatase 1-inhibitory properties. As a consequence,
protein phosphatase 1 activity is restored, dephosphorylating
IP3R1 and suppressing its Ca
2+
ﬂux properties. As such, this Bcl-2-
dependent feedback cycle prevents apoptotic Ca2+ ﬂux through
IP3R1 channels.
110,111
Not only phosphorylation events at the IP3Rs, but also
phosphorylation of Bcl-2 itself was shown to impact Bcl-2’s ability
to lower ER Ca2+ levels.112 It has long been known that JNK-
mediated phosphorylation of Bcl-2 abolishes its antiapoptotic
properties, correlating with its impaired abilities to scaffold
proapoptotic Bcl-2-family members like Bax and truncated Bid
(tBid). Consistently, a mutant version of Bcl-2 that could not be
phosphorylated by JNK was more effective than wild-type Bcl-2 to
reduce the ER Ca2+-store content. This mutant Bcl-2 displayed
improved binding to proapoptotic BH3-only proteins. Conversely,
overexpression of a Bcl-2 variant mutated in the hydrophobic cleft,
defective in binding Bax and BH3-only proteins, failed to lower the
ER Ca2+-store content. These ﬁndings indicated a link between
Bcl-2’s antiapoptotic properties as a scaffolding protein of
proapoptotic Bcl-2-family members and as an ER Ca2+-reducing
protein. It could also suggest that Bcl-2’s ability to lower ER Ca2+ is
mediated through interaction with proapoptotic Bcl-2-family
members or at least with BH3-domain-containing proteins.
As mentioned above, Bax and Bak may play important roles in
regulating the ER Ca2+ store content. In MEF Bax/Bak double
knockout cells the ER store content was shown to be lower,
resulting in less Ca2+ release from the ER and less uptake into the
mitochondria after apoptotic stimuli such as ceramide, stauros-
porine, arachidonic acid and H2O2 were used.
82 This correlated
with a reduction in apoptosis which could be countered by
overexpressing Bax or SERCA, effectively reﬁlling the ER Ca2+ store.
Conversely, overexpression of either Bax or Bak in PC3 prostate
cancer cells also resulted in a reduced ER Ca2+ pool.113 It was
shown that overexpression of Bax or Bak sensitized the
mitochondria to take up more Ca2+, thereby rendering these cells
more prone to mitochondrial Ca2+ overload and increased
cytochrome c release after induction of apoptosis by
staurosporine.113,114 Interestingly, co-overexpression of Bcl-2 with
Bax or Bak in these cells could prevent both the reduction of
the ER Ca2+ store content and the release of cytochrome c.
These results strongly suggest that the proapoptotic functions of
Bax and Bak include the regulation of the ER Ca2+ store.
Another Bcl-2 target is Bax inhibitor-1, an evolutionary
conserved member of the transmembrane Bax inhibitor-1 motif-
containing protein family with antiapoptotic properties at the
level of the ER.92,115,116 Bax inhibitor-1 function has been
implicated in the control of ER Ca2+ homeostasis117 by acting as
a H+/Ca2+ exchanger118 or a Ca2+-leak channel.119 Moreover, Bax
inhibitor-1 binds to the IP3R, thereby sensitizing the IP3R.
120 The
function of Bax inhibitor-1 is regulated by antiapoptotic Bcl-2.117
This regulation seems to involve the BH4 domain of Bcl-2: ﬁrst,
Bcl-2 lacking its BH4 domain failed to bind to Bax inhibitor-192 and
second, the BH4 domain of Bcl-2 seemed sufﬁcient to promote
Bax inhibitor-1 oligomerization and H+/Ca2+-antiporter activity.121
Furthermore, it has been proposed that the ability of Bcl-2
proteins to lower the steady-state ER Ca2+ levels was dependent
on the presence of Bax inhibitor-1117 as overexpression of
antiapoptotic Bcl-2 proteins failed to lower ER Ca2+ levels in cells
lacking Bax inhibitor-1. Hence, endogenous Bax inhibitor-1 levels
in cells could be a critical determinant for whether or not Bcl-2 is
able to lower the Ca2+-ﬁlling state of the ER. Finally, it is important
to note that other transmembrane Bax inhibitor-1 motif-family
members can impact Ca2+ signaling,122–127 but whether these
proteins are targeted and regulated by antiapoptotic Bcl-2
remains to be determined.
Bcl-2 can also modulate ER Ca2+ uptake through SERCA.96 Bcl-2
was reported to directly interact with different SERCA isoforms,
including the house-keeping SERCA2b isoform.96,128–130 However,
divergent functional outcomes have been reported. On the one
hand, Bcl-2 was shown to support SERCA activity.96,130 Bcl-2
mediates SERCA2 upregulation at both the mRNA and protein
level, thereby promoting SERCA-mediated Ca2+ uptake in the ER.96
Bcl-2 was found in SERCA2-protein complexes via a direct or
indirect association. Bcl-2 was able to desensitize SERCA pumps to
thapsigargin inhibition and also maintain ER Ca2+ homeostasis
after extracellular Ca2+ was depleted.88,130 This suggests that Bcl-2
promotes SERCA function in order to maintain proper ﬁlling of the
ER Ca2+ store. Strikingly, these effects of Bcl-2 on SERCA sensitivity
to thapsigargin required the presence of the BH4 domain.130 In
contrast, Bcl-2 has been reported to negatively impact SERCA
function. Binding of Bcl-2 to SERCA1 present in the sarcoplasmic
reticulum of skeletal muscle cells caused a partial unfolding and
concomitant destabilization of the protein, resulting in an
inhibition of the native SERCA1 activity of the sarcoplasmic
reticulum of skeletal muscle cells.128,129 Interestingly, the con-
formational changes in SERCA1 structure induced by Bcl-2 could
be prevented by heat-shock protein 70.131
The negative impact of Bcl-2 expression on SERCA2 has also
been implicated in cystic ﬁbrosis.132 Lung tissue samples of
bronchial and bronchiolar epithelia of patients with cystic ﬁbrosis
displayed a marked decline in overall SERCA Ca2+-ATPase activity
and in SERCA2-protein levels compared with samples from non-
cystic ﬁbrosis airways, correlating with an increase in Bcl-2-protein
levels and increased association of Bcl-2 with SERCA2.132
In any case, the putative negative impact of Bcl-2 on SERCA2
activity/expression could be a mechanism that contributes to the
decreased ER Ca2+ levels observed in Bcl-2-overexpressing cells.
Bcl-2 inhibits proapoptotic Ca2+ release from the ER
Besides regulating IP3R activity by modulating its PKA phosphor-
ylation state, Bcl-2 was also shown to directly inhibit IP3R-
mediated Ca2+ release, without affecting ER Ca2+ store
content.90,133,134 Bcl-2 binds to the central, modulatory domain
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of the IP3R channel. This binding site has been narrowed down to
20 amino acids (i.e. a.a. 1389–1408 of murine IP3R1).
135 The Bcl-2
domain responsible and sufﬁcient for targeting this site is the BH4
domain.134 Lys17, located in the center of the BH4 domain, is
essential for IP3R binding.
136 Interestingly, Lys17 in the BH4
domain of Bcl-2 corresponds to the Asp11 residue in the BH4
domain of Bcl-XL and seems to underlie a critical difference
between Bcl-2 and Bcl-XL, where Bcl-2 binds much better to this
IP3R domain compared to Bcl-XL. Similar to the conservation of the
Bcl-2-binding site on IP3Rs, also the Lys residue in the BH4 domain
of Bcl-2 seems to be conserved during evolution, at least in
vertebrates.137 Since other Bcl-2-family members may also contain
a BH4 consensus motif, it cannot be excluded that some of these
BH4 domains present in other Bcl-2 proteins are capable to bind
and regulate IP3Rs. However, Lys17 of Bcl-2 appears not strongly
conserved among the BH4-domain motif of other Bcl-2-family
members. Interestingly, it does correlate with a positively charged
amino acid (Arg184) in the BH4 domain of Mcl-1, a protein
implicated in IP3R binding and regulation.
138 At the functional
level, Bcl-2 binding to the central, modulatory domain of the IP3R
suppresses the Ca2+-ﬂux properties of the IP3R.
135 The BH4
domain was sufﬁcient for this.134,136,139 Although all three IP3R
isoforms are targets of Bcl-2,136 abolishing IP3R/Bcl-2 complex
formation, utilizing a peptide tool corresponding to this Bcl-2-
binding site on the IP3R, was particularly toxic in diffuse large
B-cell lymphoma cells expressing high levels of IP3R2, the IP3R
isoform with the highest afﬁnity for its ligand, IP3.
77,140 Of note,
increasing numbers of studies have reported the relevance of
IP3R2 channels for human physiology and pathophysiology,
including for senescence in tumor cells.141,142 Hence, it is clear
that Bcl-2 can function as an important functional inhibitor of IP3R
channels and thus limit proapoptotic ER–mitochondrial Ca2+
transfers. At the molecular level, the interaction of the IP3R with
the BH4 domain of Bcl-2 seems to be a low-afﬁnity interaction
(~1 μM), consistent with the relatively high IC50 (~30 μM) observed
for IP3R inhibition by the BH4 domain of Bcl-2 in permeabilized
cells.136 This may indicate that other domains are important for
targeting Bcl-2 to IP3Rs or at least to locally concentrate Bcl-2 at
the ER in the proximity of IP3Rs. Overall, these studies imply that
Bcl-2 functions as a direct inhibitor of IP3R channels without
impacting the ER Ca2+ levels.133–136
Bcl-2, Bcl-XL and Mcl-1 promote prosurvival Ca
2+ oscillations by
regulating the IP3R
In addition to the Bcl-2-binding site located in the central
modulatory domain of the IP3R, another site on the IP3R is able
to recruit antiapoptotic Bcl-2-family members. Bcl-2, Bcl-XL and
Mcl-1 can all target the C-terminal region on the IP3R.
138,143,144
This region harbors the Ca2+-permeable channel pore and makes
contact with the N-terminal IP3-binding domain.
145,146 Binding of
these Bcl-2-family members seems to depend on the presence of
the sixth transmembrane domain of the IP3R.
138,143 An interesting
hypothesis has been raised by Foskett and co-workers147
proposing the presence of BH3-domain-like structures in the
C-terminal part of the IP3Rs, which could serve as targets for the
hydrophobic cleft of Bcl-2-family proteins. However, the impor-
tance of the hydrophobic cleft of Bcl-2 for IP3R regulation ought to
be further explored. At the functional level, binding of these Bcl-2
proteins to the C-terminal site on IP3R has been implicated in the
sensitization of the IP3R channel to low IP3 concentrations thereby
promoting Ca2+-oscillations, driving mitochondrial ATP production
and bioenergetics, thus promoting cell survival.138,143,144,148 An
interesting observation was described for Bcl-XL. Although Bcl-XL
could regulate all three IP3R isoforms in this way, it was reported
that Bcl-XL binding to the type 3 IP3R also reduced the ER Ca
2+
store content.149
A recent study has underscored the signiﬁcance of IP3R/Bcl-XL
complex formation for cell survival and mitochondrial
bioenergetics.150 In particular, the C-terminal IP3R/Bcl-XL nexus
seems to be modulated by other proteins, including oncogenic
K-Ras. This mutated form of K-Ras can translocate to the ER upon
protein kinase C-mediated phosphorylation and become
proapoptotic. Protein kinase C-phosphorylated K-Ras seems to
target the IP3R/Bcl-XL complex, thereby counteracting Bcl-XL’s
antiapoptotic functions. As a consequence of the loss of its Bcl-XL
partner, IP3R-mediated Ca
2+ oscillations become strongly
impaired, impacting mitochondrial function leading to autophagy
induction.31 While controlled autophagy induction aims to
maintain cellular homeostasis and cell survival, excessive and/or
prolonged autophagy activation can result in autophagic cell
death.151 Hence, phosphorylated K-Ras induces excessive autop-
hagy and impairs mitochondrial function, leading to a form of
autophagic cell death.150
Bcl-XL regulates IP3R levels
Overexpression of Bcl-XL in FL5.12 cells, an interleukin-3-
dependent lymphoid cell line, resulted in a decrease in the
expression levels of both IP3R1 and IP3R3.
152 Consistent with the
decreased IP3R-expression levels, T-cell-receptor stimulation-
induced cytosolic [Ca2+] rise was suppressed in Bcl-XL-over-
expressing cells, and microsomes prepared from these cells
displayed a reduced IP3-induced Ca
2+ mobilization. The reduction
in IP3R-expression levels upon Bcl-XL overexpression protected
cells against thapsigargin-induced apoptosis, which could be
partially reversed by IP3R1 overexpression. This ﬁts with original
observations from other laboratories, showing that T lymphocytes
lacking IP3R1 channels are resistant to a variety of apoptotic
stimuli.153
Bok causes IP3R1 upregulation by protecting the channel from
proteolytic cleavage
A recent study indicated that the ER-localized, proapoptotic Bcl-2-
family member Bok binds to IP3Rs with a higher afﬁnity than the
other Bcl-2-family members.154 Bok was found to form native
protein complexes with IP3Rs in a variety of cell lines. In contrast to
Bcl-2, which interacts with all three IP3R isoforms, Bok binding
appeared to be selective for IP3R1 and IP3R2 channels. Bok binding
to the IP3R occurred in a region that is very near the caspase
3-cleavage site (DEVD at position 1891 in IP3R1).
155–159 Caspase
3-mediated cleavage of IP3R1 was proposed to form an ER
Ca2+-leak channel, contributing to intracellular Ca2+ overload.
However, IP3R cleavage by caspase 3 may, at least in some cases,
be a very late event and not an early driver for apoptosis.160,161
Consistent with the binding of Bok in the proximity of the DEVD
motif, it was found that Bok protected IP3R1 from proteolysis.
154
Such protection was not only observed in biochemical experi-
ments but also during apoptosis. Caspase 3-dependent IP3R1
cleavage products were more rapidly observed in Bok-deﬁcient
MEF cells than in wild-type MEF cells. Interestingly, Bok and IP3R1
degradation displayed a similar time-dependent degradation
through the ubiquitin/proteasome system in response to pro-
longed IP3R activation. Finally, Bok impacted the IP3R expression
levels. Although Bok-deﬁcient cells display increased IP3R1 levels,
wild-type and Bok-deﬁcient MEF cells displayed similar agonist-
induced Ca2+-release properties. This might be due to the fact that
the increase in IP3R1 levels in Bok-deﬁcient cells is compensated
by the decrease in IP3R2 and IP3R3 levels. This remodeling of the
expression proﬁle of IP3R isoforms might mask the ability of Bok to
directly modulate IP3R activity. Further experiments using puriﬁed
Bok or subdomains will be required to examine their direct impact
on the Ca2+-ﬂux properties of IP3R channels.
Bcl-2 proteins and calcium signaling
T Vervliet et al
6
Oncogene (2016) 1 – 14 © 2016 Macmillan Publishers Limited
Bcl-2 and Bcl-XL inhibit RyRs
RyRs have recently been identiﬁed as targets of Bcl-2 and
Bcl-XL.
91,162 The identiﬁcation of RyR/Bcl-2 complex formation
was driven by an in silico analysis, revealing that a stretch of about
20 amino acids (a.a. 2448–2469 of rabbit RyR1) located in the
central domain of the RyR displayed remarkable similarities with
the stretch of amino acids responsible for Bcl-2 binding to the
central domain of the IP3R.
91,163 Similar to the results obtained for
IP3Rs, binding of Bcl-2 to the RyR occurs via its BH4 domain
and causes an inhibition of RyR-mediated Ca2+ release. Moreover,
the BH4 domain of Bcl-2 seemed sufﬁcient for RyR binding and
inhibition. Yet, in contrast to the IP3Rs, Lys17, located in the center
of the BH4 domain of Bcl-2, was dispensable for binding of Bcl-2
to RyRs.91
Bcl-XL contains in its BH4 domain an Asp at the position
corresponding to Lys17 in Bcl-2. Since the mutation of Lys17 in
Bcl-2 did not impact its ability to interact with and inhibit RyR
channels,91 RyR regulation by Bcl-XL was recently examined,
indicating that both the BH4 and the BH3 domain of Bcl-XL played
a role in the interaction of Bcl-XL with the RyR.
162 RyR/Bcl-XL
complexes could be identiﬁed in RyR-expressing HEK293 cell
models. Overexpression of Bcl-XL resulted in a decreased RyR-
mediated Ca2+ release. The BH4 domain of Bcl-XL was found to be
able to directly bind to the same RyR fragment responsible for
binding Bcl-2 and to suppress the caffeine-induced [Ca2+] rise in
the cytosol in heterologous overexpression cell models and
dissociated hippocampal neurons.
Bcl-2-family proteins may impact the organization of the ER Ca2+
stores
Bcl-2-family members not only have direct or indirect effects on
Ca2+-transport systems but can also affect the remodeling of
whole organelles such as the ER and mitochondria.164–166 As a
consequence, Bcl-2 proteins can impact Ca2+ signaling by
controlling the overall organization of intracellular compartments
and Ca2+-storage organelles such as the ER. In particular, Bcl-XL
has been implicated in altering the properties of proapoptotic Bak
with respect to the restructuring of the ER.167 Overexpression of
Bak together with Bcl-XL or of a mutant form of Bak lacking its BH3
domain (Bak-ΔBH3) led to the induction of ER vacuolization and
swelling. Interestingly, inhibition of RyR channels by dantrolene
seems to potentiate ER vacuolization by Bak/Bcl-XL or Bak-ΔBH3
overexpression, while activation of RyR channels by caffeine
rescues their deleterious effects on the ER structure. In the
absence of RyR channel activity, Bim and tBid were able to induce
ER vacuolization in the presence of endogenous Bak, while the
presence of Bax was not critical for this phenomenon. Hence, it
seems that a RyR-mediated [Ca2+] rise in the cytosol could be
important for maintaining the organization of the ER Ca2+
stores.167
Another study highlighted the importance of the antiapoptotic
Bcl-2-family members, Bcl-2, Bcl-XL and especially Mcl-1, in the
organization of the ER compartment.168 Apogossypol, an inhibitor
of antiapoptotic Bcl-2 proteins, triggered a re-organization of the
ER membranes, which was associated with impaired ER function
and protein transport. These ER re-arrangements occurred well
before the activation of the UPR as MEF cells lacking the ER stress
sensors Ire1α, protein kinase RNA-like endoplasmic reticulum
kinase or ATF6 displayed similar ER-membrane re-arrangements as
wild-type MEF cells. Moreover, classical ER stress inducers, like
brefeldin A or tunicamycin, failed to induce these ER-membrane
re-arrangements, indicating that apogossypol led to a novel form
of ER stress. The effect of apogossypol could be mimicked by
knocking down Mcl-1, but not Bcl-2 or Bcl-XL. Inhibition of
Bcl-2 and Bcl-XL using ABT-737 potentiated the ER-membrane
re-arrangements in cells in which Mcl-1 was knocked down.
These ER-membrane re-arrangements induced by apogossypol
had important impacts on ER function and transport, since
apogossypol abrogated the trafﬁcking of the human ether-a-
gogo-related channel from the ER to the plasma membrane.168
The authors also postulated that ER-membrane re-organization
might be a common phenomenon in cells in response to diverse
pharmacological agents and might explain the cardiotoxic effects
of a number of these drugs.
Also during UPR-mediated cell death Bcl-2 proteins play
important roles. It was shown that the UPR activates Bax and
Bak at the ER and this results in a leak of ER luminal proteins
associated with UPR-mediated cell death.169 In this work Bid was
shown to play a role in activating Bax at the ER membranes.
Recent work elucidated this further and showed that during UPR
Bnip3, another proapoptotic BH3-only Bcl-2-family member,
accumulates and competes with Bax and Bak for the hydrophobic
cleft of Bcl-2, thereby activating Bax and Bak at the ER
membrane.170 The leak of ER content produced by Bax/Bak
activation resulted in increased ROS production ultimately leading
to cell death. Inhibition of Ire1α signaling was shown to be crucial
for the proapoptotic function of Bnip3 during UPR-mediated
cell death.
BCL-2-PROTEIN FAMILY TARGETS AT THE MITOCHONDRIA
Besides limiting excessive Ca2+ release towards the mitochondria,
another effective way for cancer cells to prevent mitochondrial
Ca2+ overload is to limit mitochondrial Ca2+ uptake. Also here
different antiapoptotic Bcl-2-family members are known to play
important roles.
Bcl-2 and Bcl-XL regulate mitochondrial Ca
2+ uptake through
VDAC
VDAC1 is a large conductance channel located in the outer
mitochondrial membrane that is permeable to ions and
metabolites.171 Although its name refers to its permeability to
anions, it is clear that also cations, like Ca2+, can permeate through
VDAC1.172 When VDAC1 channels close, that is being imperme-
able for ATP and metabolites, Ca2+ permeation is even
enhanced.172 As such, VDAC1 plays a critical role both in cell
survival and in cell death. On the one hand, VDAC1 mediates the
passage of prosurvival Ca2+ signals from the ER and cytosol into
the mitochondria and the exchange of ATP and other metabolites
between the mitochondria and the cytosol. VDAC1 also recruits
prosurvival proteins like hexokinase-I.173,174 On the other hand it
mediates the ﬂux of proapoptotic Ca2+ signals from the ER and the
cytosol into the mitochondria.35,175,176 IP3R channels and VDAC1
channels seem to be physically linked via a chaperone glucose-
regulated protein 75, establishing a ‘quasi-synaptic’ transfer of
Ca2+ from the ER to the mitochondria.177 In particular, VDAC1, but
not VDAC2 or VDAC3, seems to be implicated in forming
complexes with the IP3Rs and subsequent proapoptotic
Ca2+ transfer from the ER to the mitochondria.35 Given VDAC1’s
critical role in Ca2+-mediated cell survival and death decisions, it is
not surprising that Bcl-2-family proteins can directly bind to
VDAC1 channels.
Both Bcl-2 and Bcl-XL have been shown to interact with VDAC1
thereby inhibiting mitochondrial Ca2+ uptake, protecting cells
from excessive mitochondrial Ca2+ uptake.93,94,178 A critical role for
the N-terminus of VDAC1 in the binding of these Bcl-2-family
proteins was demonstrated.179,180 In particular for Bcl-XL it was
reported that, different residues and regions seem to be involved
in VDAC1 binding.181 This correlates with other ﬁndings using
VDAC1-derived peptides showing that multiple regions in the
VDAC1 channel, including a.a. 1–26, a.a. 63–78 and a.a. 199–215,
contribute to functional Bcl-XL recruitment. Furthermore, the
targeting of VDAC1 by Bcl-XL seems to involve the BH4 domain.
95
Consistent with this, the BH4 domain of Bcl-XL was sufﬁcient to
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bind to VDAC1 channels and to effectively suppress apoptotic cell
death when coupled to the TAT sequence for facilitating cell entry.
We recently conﬁrmed these ﬁndings showing that the BH4
domain of Bcl-XL but not that of Bcl-2 could interact with
VDAC1.180
Although Bcl-XL binding to VDAC1 has been proposed in
different studies to suppress proapoptotic Ca2+ uptake, a study
comparing wild-type versus Bcl-XL
− /− MEF cells indicated that the
presence of Bcl-XL promoted mitochondrial Ca
2+ uptake.182 The
mechanism involved a direct interaction of Bcl-XL with VDAC1
(and VDAC3). Moreover, VDAC1-derived peptides that disrupted
VDAC1/Bcl-XL complex formation also prevented the ability of
Bcl-XL to enhance mitochondrial Ca
2+ uptake. Recent structure–
function studies showed that the ability of Bcl-XL to promote
mitochondrial Ca2+ uptake was linked to its ability to form dimers,
a property that is facilitated by membrane recruitment and
prevented by BH3 mimetics.183 Bcl-XL mutants that cannot
dimerize failed to promote mitochondrial Ca2+ uptake. By
enhancing the mitochondrial Ca2+ uptake, Bcl-XL could increase
the activity of the Ca2+-dependent tricarboxylic acid cycle
enzymes and thus promote mitochondrial bioenergetics. We
therefore speculate that, in healthy cells not exposed to
proapoptotic stimuli or not undergoing apoptotic cell death, Bcl-
XL may function as a true prosurvival protein by enhancing the
transfer of basal Ca2+ signals from the ER into the mitochondria,
including Ca2+ oscillations that drive mitochondrial bioenergetics
and ATP synthesis.24,32,182,184 Alternatively, differences in the
experimental conditions may account for the different outcome of
the experiments.50 For instance, the study of White and his team
was based on studying mitochondrial Ca2+ uptake using
(i) permeabilized cell systems and (ii) comparing Bcl-XL-expressing
versus Bcl-XL-deﬁcient cells. However, it is reported that Bcl-XL can
impact mitochondrial organization185 and the activity of the
F-type ATPase,186 which might directly affect mitochondrial Ca2+
uptake. But, in the former study50 Bcl-XL
− /− and wild-type MEF cells
had similar mitochondrial morphology, similar number of ER–
mitochondrial contact sites and mitochondrial potential. Also, in
permeabilized cells, speciﬁc Ca2+ microdomains likely are lost and
thus properties of mitochondrial Ca2+-uptake might be altered. In
any case, studies that are based on direct VDAC1 activity,
including mitochondrial swelling assays single-channel measure-
ments and on acute addition of puriﬁed Bcl-XL/Bcl-2 or domains
derived from these proteins like the BH4 domain, showed that
Bcl-2/Bcl-XL proteins inhibited VDAC1.
95,178,180
Mcl-1 increases VDAC1-mediated Ca2+ uptake
Recently, Mcl-1 has been shown to bind to VDAC channels.187
Strong binding of Mcl-1 was observed to VDAC1 and VDAC3, while
VDAC2 displayed weak binding. The interaction of Mcl-1 with
VDAC1 seemed to enhance VDAC1-mediated Ca2+ uptake in
the mitochondria, since Mcl-1 knock down reduced the mitochon-
drial Ca2+-uptake rate. As a consequence of the increased
mitochondrial Ca2+ uptake, the presence of Mcl-1 increased the
mitochondrial production of ROS. Finally, the authors showed in
non-small-cell lung carcinoma cell lines that this Mcl-1-mediated
increase in ROS species production promoted cell migration
without impacting cell proliferation.
Bcl-2 inhibits the mitochondrial Na+/Ca2+ exchanger
In mitochondria isolated from hearts of Bcl-2-overexpressing mice,
Bcl-2 inhibited mitochondrial Na+/Ca2+ exchange activity.188 The
authors reported that Bcl-2 overexpression slowed down the rate
at which Ca2+ was extruded from the matrix. This was
accompanied by an increased capacity for Ca2+ in the mitochon-
dria and a slightly increased resting level of mitochondrial Ca2+.
Although this increase in resting state Ca2+ was only small, NADH
formation and thus mitochondrial energy production was
increased by 50%. This suggests that antiapoptotic Bcl-2 proteins
may ﬁnely regulate mitochondrial Ca2+ levels in order to promote
mitochondrial metabolism and energy production as efﬁciently as
possible.
Bcl-2-family members may impact the dynamics and function of
mitochondria
Mitochondria are constantly remodeling, thereby undergoing
mitochondrial fusion and ﬁssion, which is important for mitochon-
drial health and regulating bioenergetics. At the molecular level,
these processes are controlled by different factors responsible for
fusion, including the large GTPases mitofusins (Mfn1 and Mfn2)
that act on the outer mitochondrial membrane and optic atrophy
1 that act on the inner mitochondrial membrane and for ﬁssion,
including dynamin-related protein 1 (Drp1), ﬁssion1 and mito-
chondrial ﬁssion factor.189,190 Now, different Bcl-2-family mem-
bers, including Bax, Bak and Bcl-XL, have been shown to impact
mitochondrial dynamics by directly targeting and activating
these proteins.185,191–194 In addition, Bcl-2-family members can
also impact mitochondrial functions like metabolic efﬁciency.
Bcl-XL has been reported to directly bind the β subunit of the
F0/F1-ATP synthase, increasing its activity and thus mitochondrial
metabolism.186 Furthermore, the presence of Bcl-XL stabilized the
mitochondrial potential. Hence, these effects of Bcl-2-family
members on mitochondrial dynamics, ATP-producing systems
and mitochondrial potential could indirectly impact the ability of
the mitochondria to take up Ca2+. Now, very recently, an elegant
study using splice-switching antisense oligonucleotides showed
that switching the expression from the antiapoptotic Mcl-1 long
isoform (Mcl-1 L) to the proapoptotic Mcl-1 short isoform (Mcl-1 S)
resulted in mitochondrial hyperfusion and mitochondrial
hyperpolarization.164 This resulted in increased mitochondrial
Ca2+ accumulation and increased susceptibility to apoptotic
stimuli. The molecular mechanism involved the mitochondrial
ﬁssion factor Drp1, which was recruited to the outer mitochondrial
membranes via a direct interaction with Mcl-1 L. In comparison
with Mcl-1 S, Mcl-1 L is enriched at the mitochondria, where it is
proposed to serve as an anchor for Drp1 to promote ﬁssion and
prevent apoptosis.
BCL-2-PROTEIN FAMILY TARGETS AT THE PLASMA
MEMBRANE: PMCA
PMCA is a family of Ca2+ ATPases, involved in Ca2+ extrusion over
the plasma membrane.9 Multiple PMCA isoforms exist and are
broadly expressed in a wide variety of cell types and tissues.195,196
PMCA is critical in removing Ca2+ from the cytosol and together
with SERCA helps to lower cytosolic Ca2+ after agonist-induced
Ca2+ signaling.9 Hence, an inhibition of PMCA activity will cause
prolonged Ca2+ signals in the cytosol and could indirectly increase
the amount of mitochondrial Ca2+ uptake. Recently, Bcl-2 proteins
have been implicated in controlling PMCA activity, although a
direct interaction between both proteins was not demonstrated.97
Increasing Bcl-2 levels caused an inhibition of PMCA, while
lowering Bcl-2 levels resulted in increased PMCA activity. Bcl-2
knockout pancreatic acinar cells consequently demonstrated
higher levels of apoptosis, when stressed with menadione or
increased extracellular Ca2+, but less necrosis, indicating a shift in
the cell death program. In contrast, in the presence of the PMCA
inhibitor caloxin 3A1, necrotic cell death was increased. Since Bcl-
2’s presence in the plasma membrane seems unlikely, ER–plasma
membrane contact sites197 may be critical for Bcl-2/PMCA
complex formation. This may allow ER-located Bcl-2 to interact
with plasma membrane-located PMCA. In that sense, studying the
role of PMCA regulation in cells displaying impaired ER–plasma
membrane contact site, like protein kinase RNA-like endoplasmic
reticulum kinase-deﬁcient cells198 or junctate-deﬁcient cells,199,200
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may be relevant. Of note, in DT40 cells and mouse B cells, a low
number of IP3R channels has been found to be present in the
plasma membrane, where they form functional channels that
contribute to Ca2+ entry upon B-cell receptor stimulation.201 As
such, if Bcl-2 from the ER is capable of controlling PMCA, it might
also control these plasmalemmal IP3Rs.
TARGETING BCL-2-PROTEIN FAMILY ACTIONS FOR CANCER
TREATMENT
With regard to cancer treatment, major efforts have been made to
develop drugs targeting the hydrophobic cleft of antiapoptotic
Bcl-2 proteins: the so-called BH3 mimetics.68,69 These drugs bind
to the hydrophobic cleft of antiapoptotic Bcl-2-family members
thereby releasing and activating the proapoptotic family members
ultimately leading to Bax/Bak activation and apoptosis. The ﬁrst
generation of such drugs like ABT-737 and ABT-263 targeted
both Bcl-2 and Bcl-XL.
68 However, these drugs caused severe
thrombocytopenia, limiting their therapeutic use for the treatment
of Bcl-2-dependent cancers like chronic lymphocytic leukemia.202
The second-generation drugs, like ABT-199, selectively target Bcl-2
and are promising tools for several Bcl-2-dependent cancers.69
They are currently in phase III clinical trials where they are applied
to treat relapsed chronic lymphocytic leukemia patients.
Although not extensively studied, BH3-mimetic drugs might
also affect Ca2+ signaling, thereby impacting or modulating its cell
death properties in cancer cells. The reason for this is that (i) the
proapoptotic Bcl-2-family members also play important roles in
modulating ER Ca2+ levels and in regulating ER integrity, and
(ii) Ca2+-release channels like the IP3R may contain BH3-domain-
like sequences that participate in Bcl-2 recruitment and functional
regulation by Bcl-2-family members.147 In platelets, ABT-737, a
non-selective Bcl-2/Bcl-XL antagonist, was shown to disturb
intracellular Ca2+ homeostasis, which was proposed to cause or
at least contribute to ABT-737-induced toxicity in platelets.203
However, subsequent studies showed that ABT-737 did not
mobilize intracellular Ca2+ or altered thrombin-induced Ca2+
transients in platelets.204 This was supported by a detailed analysis
revealing that ABT-737 did not impact the ER Ca2+-uptake and
-release mechanisms in platelets or in other human cell lines.205
Thus, the disturbed intracellular Ca2+ homeostasis is rather a
consequence than a cause of platelet death induced by the
inhibition of Bcl-XL by ABT-737. Similar results were obtained in
Bcl-2-dependent chronic lymphocytic leukemia cancer cells,
in which acute application of ABT-737 did not trigger changes
in cytosolic [Ca2+].206
It has been shown that abolishing the binding of Bcl-2 to the
central IP3R domain using Bcl-2 IP3 Receptor Disruptor-2 (BIRD-2),
a peptide tool covering the Bcl-2-binding site on the IP3R,
enhances proapoptotic Ca2+-signaling events in T cells in
response to T-cell-receptor stimulation135. BIRD-2 triggers sponta-
neous apoptotic Ca2+-signaling events in malignant cells, includ-
ing primary lymphocytes obtained from chronic lymphocytic
leukemia,206,207 diffuse large B-cell lymphoma cell lines,140 multi-
ple myeloma, follicular lymphoma cells,208 and small cell lung
cancer cells.209 The apoptotic response of diffuse large B-cell
lymphoma cancer cells was linked to the expression level of IP3R2
channels, the IP3R isoform displaying the highest sensitivity to its
ligand IP3.
140 This indicates that antagonizing Bcl-2’s function at
the level of the IP3R at the ER may hold therapeutic potential in at
least subset of cancer cells.77 Furthermore, a synergism between
BIRD-2 and BH3 mimetics was discovered.209 Prolonged incuba-
tion of cancer cells with BIRD-2 resulted in a Ca2+-dependent
upregulation of proapoptotic Bim, rendering these cells sensitive
to ABT-199.208 As the use of peptides as therapeutic drugs is
limited, the development of small molecules mimicking BIRD-2
function is crucial for targeting the Bcl-2/IP3R interaction. Recently
a small molecule, BDA-366, that binds the BH4 domain of Bcl-2
with very high afﬁnity and selectivity was discovered.210,211
BDA-366 was shown to induce apoptosis in a Bax-dependent
way in lung cancer cells grafted into mouse models.76 The binding
of BDA-366 to the BH4 domain of Bcl-2 induced conformational
changes in Bcl-2 thereby exposing the BH3 domain of Bcl-2
resulting in a loss of Bcl-2’s prosurvival functions.76,212,213 The
compound was also shown to reduce binding of Bcl-2 to the IP3R
resulting in an increased Ca2+ release. Although BDA-366 shows
great promise in this lung cancer xenograft model, its cell-death
properties ought to be assessed in other cancer cells and models
and its impact on IP3R/Bcl-2 interaction ought to be characterized
in more detail.
CONCLUSIONS
In this review, we have discussed various mechanisms in which
Bcl-2-family proteins can modulate intracellular Ca2+ transport
systems (Table 1). In cancer cells, antiapoptotic Bcl-2 proteins
usually depress proapoptotic Ca2+ signals and at the same time
promote prosurvival Ca2+ oscillations (Figure 1). Also by ﬁnely
regulating the mitochondrial Ca2+ uptake, Bcl-2-family proteins
can maximize the positive effects of Ca2+ on mitochondrial
bioenergetics while still protecting them from Ca2+ overload and
cell death. Many cancers have elevated levels of antiapoptotic Bcl-
2 proteins. The development of the BH3-mimetic drugs targeting
the hydrophobic cleft are successful in treating many of these
cancers. However, some are still resistant to these drugs and
alternatives need to be considered. The BH4 domain of Bcl-2 may
be a suitable drug target. As the BH4 domain is not part of the
hydrophobic cleft, the BH3 mimetics and BH4-domain antagonists
may have additive or even synergistic actions on certain cancer
cells. However this will need further investigation.
The regulation of intracellular Ca2+ signaling by the Bcl-2-
protein family is extremely complex. In this review we propose
that the controversy concerning the role of this protein family
in controlling Ca2+ signaling reﬂects the diversity of the
Ca2+-transport systems that are directly or indirectly targeted
and modulated by Bcl-2-family proteins and of the different
effects they can have on these Ca2+-transport systems. As a
concluding remark we would therefore like to propose at least
four levels of complexity by which Bcl-2 proteins can affect Ca2+
signaling: (i) Bcl-2-family proteins may target and/or modulate
various Ca2+-transport systems located in different cellular
compartments, (ii) Bcl-2-family proteins may have multimodal
regulatory actions on a given Ca2+-transport system, (iii) Bcl-2-
family proteins may affect the expression levels of Ca2+-transport
systems and (iv) Bcl-2-family proteins may impact the organization
of Ca2+ stores like the ER.
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